medscape.com
Metabolic Profiles May Predict IBD up to 10 Years Before Onset
If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the finding is preliminary and not yet a clinical test for prediction or treatment decisions.
Researchers studying IBD pathogenesis and biomarkers, clinicians interested in early detection research, and adult patients and caregivers following advances in IBD prediction research.
What To Know
What to know A new study presented at ECCO 2025 tested blood metabolomic profiles in large biobank cohorts and found that multiple metabolite markers — especially glycoprotein acetyls, a marker of systemic inflammation — were associated with future risk of Crohn’s disease and ulcerative colitis up to 10 years before diagnosis.
The researchers built a multi-biomarker metabolomics score that predicted Crohn’s disease (AUC ~0.73) and ulcerative colitis (AUC ~0.62) in validation biobanks, but adding genetic risk scores and routine blood markers produced little improvement and the combined model weakly predicted severe progression (emergency admission, surgery, or death).
The study used nuclear magnetic resonance metabolomics on UK Biobank participants and validated findings in Estonian and Finnish biobanks. Limitations noted include older and relatively homogeneous populations and limited information on other risk factors.
This was a conference presentation rather than a peer-reviewed full journal report; results are preliminary and replication in broader, diverse populations is needed before clinical use.
Bottom line: the work suggests blood metabolite patterns change years before IBD diagnosis and could help research into disease mechanisms and early detection, but it does not establish a clinical test or change current care.
Results come from a conference presentation using large Northern European biobanks and nuclear magnetic resonance assays by Nightingale Health; the cohorts are older and ethnically homogeneous, and the analysis is preliminary.
The study’s predictive performance was moderate and did not substantially improve when combined with genetic or routine blood measures; thus no immediate clinical application is indicated.
